Background and aims In the UK, a seven valent pneumococcal conjugate vaccine (PCV7) was introduced in 2006 for children under 2 years of age in a 3 dose schedule; 2, 4, 12 months of age and was found to be highly effective against vaccine-types, but serotype replacement reduced the overall impact against pneumococcal disease. In April 2010 PCV13 replaced PCV7 in the routine infant schedule without a catch-up campaign. We assessed the prevalence and serotype distribution of pneumococcal nasopharyngeal carriage in 3 generations prior to widespread use of PCV13.
Methods Children who received 3 doses of PCV7 (age range 21– 55 months), their parents and a cohort of community-dwelling adults aged 65 and over were recruited. A swab was taken, placed in STGG media and cultured within 8 hours. Pneumococci were cultured, serotyped using the Quellung reaction and genotyped using multilocus sequence typing.
Results S.pneumoniae was recovered from 46% (270/592) of children, 12% (12/100) of parents and 6.2% (37/600) of older adults.
PCV13 vaccine-types were found in 20% of children (56/270).The 10 most common serotypes among children, in descending order, were: 19A, 11A, 23B, 6C, nontypeables, 3, 22F, 23A, 35F and 21. 4/12 serotypes in parents and 3/37 in older adults were vaccine-types.
Conclusions 18 months after the launch of PCV13 in the UK, vaccine-type pneumococci were still circulating among preschool children although most isolates were non-vaccine types. Carriage rates in parents and older adults were lower. Further studies will allow monitoring of the impact of the vaccine once PCV13 immunity is fully established in early childhood.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.